Shao-Lee Lin, M.D., Ph.D., is a physician-scientist and biotechnology leader dedicated to discovering and developing transformative medicines for patients living with serious immune-mediated diseases. Throughout her career, she has combined scientific innovation with an unwavering patient-first philosophy, building high-performing teams focused on turning breakthrough science into life-changing therapies.
As President, Chief Executive Officer and Board Director of Cue Biopharma (NASDAQ: CUE), Dr. Lin is leading the company’s mission to develop precision immuno-engineered therapies designed to deliver functional cures for immune disorders with high unmet need. She believes the greatest advances in medicine come from combining bold scientific thinking, urgency, collaboration, and an uncompromising focus on patients.
Over more than 25 years, Dr. Lin has helped bring innovative medicines from discovery through global development and regulatory approval to patients. Before joining Cue Biopharma, she founded ACELYRIN (NASDAQ: SLRN), taking the company from inception to successful public offering within three years while raising more than $1 billion from leading biotechnology investors. She also serves as CEO and Board Chair of AZEO BIO, Inc., a privately held biotechnology company she founded in 2024.
Previously, as the first Chief Scientific Officer and Head of Research & Development at Horizon Therapeutics, Dr. Lin helped transform the company into a leading biopharmaceutical organization. Under her scientific leadership, Horizon secured FDA approval of Tepezza®, the first treatment for the vision-threatening autoimmune condition, thyroid eye disease.
Earlier in her career, Dr. Lin led Therapeutic Areas, Development Excellence, and International Development at AbbVie, where she helped to build and advance a portfolio of important new medicines, including Skyrizi® and Rinvoq®. Her organizations successfully brought multiple blockbuster new therapies from proof of concept to regulatory submissions across global regions and with consistently accelerated timelines. Prior to AbbVie, she served as Vice President of Inflammation and Respiratory Development at Gilead Sciences and held leadership positions of increasing responsibility at Amgen.
Dr. Lin earned her undergraduate degrees in Chemical Engineering and Biochemistry, graduating magna cum laude from Rice University, and received both her M.D. and Ph.D. from the Johns Hopkins University School of Medicine. She was faculty as Clinical Scholar at The Rockefeller University prior to joining industry and has also served as adjunct faculty in medicine at Cornell, UCLA, Stanford, and Northwestern.
In addition to her executive leadership, Dr. Lin has served on the boards of Principia Biopharma (NASDAQ: PRNB; acquired by Sanofi), Third Harmonic Bio (NASDAQ: THRD) and Surrozen (NASDAQ: SRZN), as well as nonprofit organizations including Lake Forest College and the Rice University School of Engineering.
What is Shao-Lee Lin's net worth?
The estimated net worth of Shao-Lee Lin is at least $19.35 million as of August 12th, 2026. Dr. Lin owns 724,253 shares of Cue Biopharma stock worth more than $19,345,522 as of August 25th. This net worth approximation does not reflect any other investments that Dr. Lin may own. Learn More about Shao-Lee Lin's net worth.
How do I contact Shao-Lee Lin?
Has Shao-Lee Lin been buying or selling shares of Cue Biopharma?
In the last ninety days, Shao-Lee Lin has sold $1,606,543.96 in Cue Biopharma stock. Most recently, Shao-Lee Lin sold 18,258 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $28.62, for a transaction totalling $522,543.96. Following the completion of the sale, the chief executive officer now directly owns 705,995 shares of the company's stock, valued at $20,205,576.90. Learn More on Shao-Lee Lin's trading history.
Who are Cue Biopharma's active insiders?
Are insiders buying or selling shares of Cue Biopharma?
In the last year, insiders at the sold shares 4 times. They sold a total of 72,715 shares worth more than $2,041,555.09. The most recent insider tranaction occured on August, 13th when CEO Shao-Lee Lin sold 18,258 shares worth more than $522,543.96. Insiders at Cue Biopharma own 14.6% of the company.
Learn More about insider trades at Cue Biopharma. Information on this page was last updated on 8/13/2026.
